{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:33:11Z","timestamp":1771007591429,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ijantimicag.2018.04.011","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T17:54:33Z","timestamp":1523728473000},"page":"451-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Carbapenems vs. alternative \u03b2-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-1385","authenticated-orcid":false,"given":"J Nicholas","family":"O'Donnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-5434","authenticated-orcid":false,"given":"Nathaniel J","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Jett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-6130","authenticated-orcid":false,"given":"Marc H","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0001","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MCP.0b013e32835f27be","article-title":"Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management","volume":"19","author":"Barbier","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0003","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00134-004-2292-7","article-title":"Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity","volume":"30","author":"Clec'h","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0004","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.TA.0000141890.29032.9A","article-title":"Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients","volume":"58","author":"Mueller","year":"2005","journal-title":"J Trauma"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0006","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcrc.2007.08.007","article-title":"Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis","volume":"23","author":"Kuti","year":"2008","journal-title":"J Crit Care"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.04.011_bib0008","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Executive summary: Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0009","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0011","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2018.04.011_bib0012","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1086\/653057","article-title":"Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!","volume":"51","author":"Ambrose","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0013","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/civ498","article-title":"Recent Updates on the role of pharmacokinetics-pharmacodynamics in antimicrobial susceptibility testing as applied to clinical practice","volume":"61","author":"Labreche","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0014","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2017.09.019","article-title":"Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung","volume":"36","author":"Rodvold","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0015","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1097\/01.CCM.0000069734.38738.C8","article-title":"Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia","volume":"31","author":"Boselli","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0016","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/CCM.0b013e318170ba21","article-title":"Alveolar concentrations of piperacillin\/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia","volume":"36","author":"Boselli","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0017","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00134-006-0401-5","article-title":"Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia","volume":"32","author":"Boselli","year":"2006","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0018","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.01330-10","article-title":"Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0019","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/clpt.2014.131","article-title":"Pulmonary penetration of piperacillin and tazobactam in critically ill patients","volume":"96","author":"Felton","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0020","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1128\/AAC.00160-07","article-title":"Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro","volume":"51","author":"Henrichfreise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0021","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1128\/AAC.00065-10","article-title":"The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression","volume":"54","author":"Louie","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0022","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1128\/AAC.00867-13","article-title":"Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa","volume":"57","author":"Felton","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0023","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0024","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0025","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0026","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/AAC.42.11.2966","article-title":"Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis","volume":"42","author":"Jaccard","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0027","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.rmed.2006.01.004","article-title":"Comparison of piperacillin\/tazobactam and imipenem\/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia","volume":"100","author":"Joshi","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0028","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study","volume":"24","author":"Rea-Neto","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s15010-006-5020-0","article-title":"Piperacillin\/tazobactam vs imipenem\/cilastatin in the treatment of nosocomial pneumonia\u2013a double blind prospective multicentre study","volume":"34","author":"Schmitt","year":"2006","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0030","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0031","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1183\/09031936.00080206","article-title":"Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia","volume":"29","author":"Siempos","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0032","first-page":"62","article-title":"Intrapulmonary pharmacokinetics of relebactam, a novel beta-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects","author":"Rizk","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0033","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00003088-200645080-00001","article-title":"Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis","volume":"45","author":"Roberts","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0034","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2005.08.015","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem","volume":"26","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2018.04.011_bib0036","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/653053","article-title":"Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51","author":"Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0037","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/378702","article-title":"Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections","volume":"37","author":"Solomkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0038","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0039","first-page":"789","article-title":"Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities","volume":"3","author":"Walsh","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0040","year":"2013","journal-title":"M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement"},{"key":"10.1016\/j.ijantimicag.2018.04.011_bib0041","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1155\/2014\/265981","article-title":"Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012","volume":"25","author":"Rennie","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T12:03:15Z","timestamp":1539086595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918301134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0924857918301134"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.04.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbapenems vs. alternative \u03b2-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}